Unichem Laboratories Downgraded to 'Sell' Rating

Dec 20 2023 12:00 AM IST
share
Share Via
Unichem Laboratories, a smallcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMojo due to its high debt and poor long-term growth. Its recent financial results also show a decline, and the stock is trading at a risky level. However, there are some positive factors such as a mildly bullish range and increased promoter confidence. Overall, the outlook for the company is negative and investors should carefully consider these factors before investing.
Unichem Laboratories Downgraded to 'Sell' Rating
Unichem Laboratories, a smallcap pharmaceutical company, has recently been downgraded to a 'Sell' by MarketsMOJO on December 20, 2023. This decision was based on several factors that indicate a negative outlook for the company.
One of the main reasons for the downgrade is the company's low ability to service its debt, with a high Debt to EBITDA ratio of -1.00 times. This means that the company may struggle to make payments on its debt obligations, which can have a negative impact on its financial stability. In addition, Unichem Laboratories has shown poor long-term growth, with net sales growing at an annual rate of only 5.55% and operating profit at 1.17% over the last 5 years. This indicates a lack of strong performance and potential for future growth. The company's recent financial results for September 2023 also show a decline, with the lowest cash and cash equivalents at Rs 64.56 crore and the highest interest at Rs 6.73 crore. This further adds to the concerns about the company's financial health. Moreover, the stock is trading at a risky level compared to its historical valuations. While it has generated a return of 29.56% in the past year, its profits have fallen by -215.4%, indicating a negative trend. However, there are some positive factors to consider. The stock is currently in a mildly bullish range, and multiple technical indicators such as RSI, MACD, KST, and OBV are showing bullish signals. Furthermore, there has been a rise in promoter confidence, with promoters increasing their stake in the company by 19.28% in the previous quarter. This is a positive sign, as it shows that the promoters have high confidence in the future of the business. In terms of market performance, Unichem Laboratories has outperformed the market (BSE 500) with a return of 29.56% in the last year, compared to the market's return of 18.57%. In conclusion, while Unichem Laboratories may have some positive aspects, the overall outlook for the company is negative. Investors should carefully consider these factors before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News